For the quarter ended June 2024, Ionis Pharmaceuticals (IONS) reported revenue of $225 million, up 19.7% over the same period last year. EPS came in at -$0.45, compared to -$0.60 in the year-ago quarter. The reported revenue represents a surprise of +52.56% over the Zacks Consensus Estimate of $147.49 million. With the consensus EPS estimate being -$0.95, the EPS surprise was +52.63%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 52.63%. A quarter ago, it was expected that this drug discovery and development company would post a loss of $1.10 per share when it actually produced a loss of $0.98, delivering a surprise of 10.91%. Over the last ...

Core Insights - Ionis Pharmaceuticals is making significant progress with its product launches, including WAINUA for hereditary ATTR polyneuropathy, which is approved in Canada and has a PDUFA date of December 19, 2024, for the U.S. market [1][2] - The company reported a 20% increase in revenue for Q2 2024 compared to the same period last year, driven by R&D revenue growth [5][11] - Ionis is on track to meet its 2024 financial guidance and is preparing for multiple upcoming product launches, including olezarsen and donidalorsen [2][5] Financial Performance - Total revenue for Q2 2024 was $225 million, up from $188 million in Q2 2023, while total revenue for the first half of 2024 reached $345 million, compared to $319 million in the same period last year [6][11] - Operating expenses increased to $291 million in Q2 2024 from $279 million in Q2 2023, reflecting strategic investments in late-stage development and commercialization efforts [5][13] - The company reported a net loss of $66 million for Q2 2024, compared to a net loss of $91 million in Q2 2023 [26] Product Development and Pipeline - WAINUA generated sales of $16 million in Q2 2024, contributing to royalty revenue of $4 million [5][7] - Olezarsen has achieved multiple clinical and regulatory milestones, with a focus on familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG) [7][8] - Donidalorsen is positioned to become the first RNA-targeted prophylactic treatment for hereditary angioedema (HAE), with positive Phase 3 data presented [7][8] Market Position and Strategy - Ionis is focused on advancing its pipeline of innovative medicines, including ION582 for Angelman syndrome, which is set to enter Phase 3 studies in H1 2025 [2][8] - The company is strategically investing in its capabilities to support the upcoming launches of olezarsen and donidalorsen, aiming for sustainable growth [10][14] - Ionis continues to explore collaborations and licensing agreements to enhance its market presence and revenue streams [12][28]

Ionis Pharmaceuticals (IONS) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 1, 2024, might help the stock move higher if these key numbers are better ...

Loading... Ionis Pharmaceuticals Inc IONS released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS). AS is a rare neurodevelopmental disorder caused by a loss of function in the maternal UBE3A gene. It affects an estimated 1 in 21,000 people worldwide. The data demonstrated consistent and encouraging clinical improvement on assessing all functional domains, including communication, cognition, and motor f ...

Core Insights - Ionis Pharmaceuticals announced positive results from the Phase 1/2 study of ION582 for Angelman syndrome, showing significant clinical improvements in communication, cognition, and motor function [1][2][3] - 97% of patients in the medium and high dose groups experienced improvement in overall Angelman syndrome symptoms as measured by the SAS-CGI-C [1][3] - Ionis plans to initiate Phase 3 development of ION582 in the first half of 2025 [1][2][4] Study Results - The HALOS study included 51 participants aged 2 to 50, demonstrating consistent benefits across all ages and genotypes [3][7] - Improvements in key functional areas exceeded those observed in natural history studies, with significant enhancements noted in the Bayley-4 assessments [3][4] - The study reported favorable safety and tolerability for ION582 at all dose levels [1][3] Assessment Tools - The study utilized various assessment tools, including Bayley-4, Vineland-3, ORCA, and SAS-CGI-C, to evaluate improvements in cognition, communication, and motor function [4][5] - Specific improvements included: - Cognition: 67% improvement on Bayley-4 - Receptive Communication: 67% on Bayley-4, 89% on Vineland-3 - Expressive Communication: 69% on Bayley-4, 84% on Vineland-3 - Gross Motor: 46% on Bayley-4, 53% on Vineland-3 - Fine Motor: 72% on Bayley-4, 63% on Vineland-3 - Daily Living Skills: 74-82% on Vineland-3 [5][6] Future Plans - Ionis intends to meet with regulators to confirm the Phase 3 study design later this year, aiming for a pivotal study initiation in H1 2025 [4][7] - The company is focused on developing transformative medicines for neurological conditions, with ION582 positioned as a cornerstone of its future pipeline [2][10]

Though IONS did not specify the total number of patients enrolled in the study, a government website states that the study has a target enrolment of nearly 73 study participants aged between two to 65 with AxD across eight countries. AxD is a rare neurological disease that affects a type of cell in the brain called astrocytes, which have multiple roles in the brain to support neurons and oligodendrocytes. People living with this condition are marked by cognitive dysfunction and progressive neurologic deteri ...

CARLSBAD, Calif., July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, August 1st at 11:30 a.m. Eastern Time to discuss its second quarter 2024 financial results. About Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals Investor Contact: D. Wade Walke, Ph.D. – [email protected] – 760-603-2331 SOURCE Ionis Pharmaceuticals, Inc. Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time The webcast may be accessed at htt ...

Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition AxD is estimated to occur in an estimated one in one million people in the U.S. and can present throughout life.1-3 The disease is a result of genetic variants in the glial fibrillary acidic protein (GFAP) gene that disrupt the structure and function of astrocytes in the brain. AxD is generally characterized by cognitive dysfunction and progressive neur ...

CARLSBAD, Calif., July 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio. About Ionis Pharmaceuticals, Inc ...